Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates. Issue 42 (9th October 2017)

• Record Type: Journal Article
• Authors: Kroiss, Steve J.; Famulare, Michael; Lyons, Hil; McCarthy, Kevin A.; Mercer, Laina D.; Chabot-Couture, Guillaume
• Is Part Of: Vaccine. Volume 35:Issue 42(2017)
• Page Start: 5674
• Page End: 5681
• Publication Date: 2017-10-09
• Subjects: cVDPV circulating (demonstrating sustained person-to-person transmission) vaccine-derived poliovirus -- mOPV2 monovalent oral polio vaccine containing only Sabin 2 -- NP-AFP non-polio acute flaccid paralysis -- OPV oral polio vaccine -- RI routine immunization -- SIA supplemental immunization activity -- SL2 Sabin-like type 2 viruses -- tOPV trivalent oral polio vaccine containing Sabin 1, 2, and 3 -- VAPP vaccine-associated paralytic polio -- VDPV vaccine-derived polioviruses; Polio -- Vaccination -- Oral polio vaccine -- Sabin -- cVDPV -- Cessation; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.08.048
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: The globally synchronized removal of the attenuated Sabin type 2 strain from the oral polio vaccine (OPV) in April 2016 marked a major change in polio vaccination policy. This change will provide a significant reduction in the burden of vaccine-associated paralytic polio (VAPP), but may increase the risk of circulating vaccine-derived poliovirus (cVDPV2) outbreaks during the transition period. This risk can be monitored by tracking the disappearance of Sabin-like type 2 (SL2) using data from the polio surveillance system. We studied SL2 prevalence in 17 countries in Africa and Asia, from 2010 to 2016 using acute flaccid paralysis surveillance data. We modeled the peak and decay of SL2 prevalence following mass vaccination events using a beta-binomial model for the detection rate, and a Ricker function for the temporal dependence. We found type 2 circulated the longest of all serotypes after a vaccination campaign, but that SL2 prevalence returned to baseline levels in approximately 50 days. Post-cessation model predictions identified 19 anomalous SL2 detections outside of model predictions in Afghanistan, India, Nigeria, Pakistan, and western Africa. Our models established benchmarks for the duration of SL2 detection after OPV2 cessation. As predicted, SL2 detection rates have plummeted, except in Nigeria where OPV2 use continued for some time in response to recent cVDPV2 detections. However, the anomalous SL2 detections suggest specific areas that merit enhanced monitoring for signs of cVDPV2 outbreaks.